Abstract: This invention provides fused heterocycles having the formula: in which R1 is a member selected from the group consisting of H, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R2 is a member selected from the group consisting of H substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R3is a member selected from the group consisting of H, C1-C6 substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R4 is a member selected from OH and O?X+, in which X+ is positive ion which is a member selected from organic positive ions and inorganic positive ions. Substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl moieties have the formula: in which Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.

Abstract: The invention is directed to racemic and stereomerically pure compounds of Formula 3: and to pharmaceutical compositions comprising them, methods of their use, and methods of their preparation.

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Abstract: A method is delineated for detecting and locating coronary artery and heart disease comprising the steps of obtaining electrocardiograph (EKG) signals from a patient, modifying the EKG signals, and establishing a base value for use in evaluating modified EKG signals. The step of modifying includes the steps of amplifying the EKG signals, digitizing amplified EKG signals, mathematically modifying the amplified and digitized EKG signals to obtain 12 lead signals in the time domain, and converting the 12 lead signals into power spectrum signals in the frequency domain. The base value is obtained by taking a patient's resting heart rate in beats per minute, converting it to beats per second, and multiplying by a scaling quantity between approximately 3 and 7, inclusively. Then, a first area is calculated by integrating a selected one of the power spectrum signals from zero Hertz to the base value. Similarly, a second area results from integrating the selected power spectrum signal from the base value to infinity.

Abstract: A method is delineated for detecting and locating coronary artery and heart disease comprising the steps of obtaining electrocardiograph (EKG) signals from a patient, modifying the EKG signals, and establishing a base value for use in evaluating modified EKG signals. The step of modifying includes the steps of amplifying the EKG signals, digitizing amplified EKG signals, mathematically modifying the amplified and digitized EKG signals to obtain 12 lead signals in the time domain, and converting the 12 lead signals into power spectrum signals in the frequency domain. The base value is obtained by taking a patient's resting heart rate in beats per minute, converting it to beats per second, and multiplying by a scaling quantity between approximately 3 and 7, inclusively. Then, a first area is calculated by integrating a selected one of the power spectrum signals from zero Hertz to the base value. Similarly, a second area results from integrating the selected power spectrum signal from the base value to infinity.

Abstract: A method is delineated for detecting and locating coronary artery and heart disease comprising the steps of obtaining electrocardiograph (EKG) signals from a patient, modifying the EKG signals, and establishing a base value for use in evaluating modified EKG signals. The step of modifying includes the steps of amplifying the EKG signals, digitizing amplified EKG signals, mathematically modifying the amplified and digitized EKG signals to obtain 12 lead signals in the time domain, and converting the 12 lead signals into power spectrum signals in the frequency domain. The base value is obtained by taking a patient's resting heart rate in beats per minute, converting it to beats per second, and multiplying by a scaling quantity between approximately 3 and 7, inclusively. Then, a first area is calculated by integrating a selected one of the power spectrum signals from zero Hertz to the base value.

Abstract: Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.